Stock Events

Stock Events

Immage Biotherapeutics 

$0
2
+$0+0% Friday 21:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
1,000
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28FebExpected
Q2 2015
Q3 2015
Q4 2015
Q1 2016
Q2 2016
Q3 2016
Q4 2016
-0.01
-0.01
-0
0
Expected EPS
0
Actual EPS
-0.0003

Financials

-Profit Margin
Unprofitable
2016
2017
0Revenue
-1.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMMG. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. develops oncology drugs and immunotherapies that directly compete with IMMG's cancer treatment technologies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in developing various cancer therapies, including immunotherapies that overlap with IMMG's product lines.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of oncology drugs and has been expanding its presence in the immunotherapy market.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG operates in the oncology sector, focusing on personalized medicine and immunotherapy, similar to IMMG's approach.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on innovative medicines in oncology, directly competing with IMMG in the cancer treatment space.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its strong presence in the oncology and immunotherapy fields, competing in the same market as IMMG.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. develops a range of biologic therapies in oncology, which competes with IMMG's biotechnological approaches to cancer treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is a biotech firm that develops monoclonal antibodies for cancer treatment, similar to IMMG's focus.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a significant investment in developing cancer therapies, including those that use mechanisms similar to IMMG's.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division, develops drugs that target various cancer types, competing with IMMG's therapies.

About

Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015. The company was founded in 2012 and is headquartered in Bethesda, Maryland. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited.
Show more...
CEO
Mr. Zhi Cong Mou
Employees
3
Country
US
ISIN
US45250J1007

Listings

OTC Link
US
IMMG

0 Comments

Share your thoughts

FAQ

What is Immage Biotherapeutics stock price today?▼
The current price of IMMG is $0 USD — it has increased by +0% in the past 24 hours. Watch Immage Biotherapeutics stock price performance more closely on the chart.
What is Immage Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immage Biotherapeutics stocks are traded under the ticker IMMG.
Is Immage Biotherapeutics stock price growing?▼
IMMG stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Immage Biotherapeutics has showed a +0% increase.
What were Immage Biotherapeutics earnings last quarter?▼
IMMG earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immage Biotherapeutics revenue for the last year?▼
Immage Biotherapeutics revenue for the last year amounts to 0 USD.
What is Immage Biotherapeutics net income for the last year?▼
IMMG net income for the last year is -1.72M USD.
How many employees does Immage Biotherapeutics have?▼
As of April 03, 2026, the company has 3 employees.
When did Immage Biotherapeutics complete a stock split?▼
The last stock split for Immage Biotherapeutics was on February 13, 2015 with a ratio of 273:1.
Where is Immage Biotherapeutics headquartered?▼
Immage Biotherapeutics is headquartered in Bethesda, US.